Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio per valutare l'efficacia e la sicurezza di ABC008 per la miosite da corpi inclusi

8 settembre 2026 aggiornato da: Abcuro, Inc.

Uno studio di fase II/III randomizzato, in doppio cieco, controllato con placebo, multicentrico per valutare l'efficacia e la sicurezza di ABC008 nel trattamento di soggetti con miosite da corpi inclusi

A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis

Panoramica dello studio

Stato

Completato

Condizioni

Miosite da corpi inclusi

Intervento / Trattamento

Droga: ABC008

Descrizione dettagliata

A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis Detailed Description: A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis Detailed Description: This is a Phase II/III randomized, double-blind, placebo-controlled, parallel multicenter study with 3 parts.

The study will include a sentinel cohort (Part A) of 30 subjects who will receive first three doses of the study drug. Safety data from subjects in the sentinel cohorts will be evaluated by a Data and Safety Monitoring Board (DSMB) before further dosing of the sentinel cohort, as well as initiation of enrollment in the double-blind safety and efficacy cohort (Part B). After completion of Part A or Part B, subjects have the option of enrolling in an open-label long-term extension study or progressing to the pharmacodynamics (PD) recovery cohort (Part C), to evaluate the recovery of the depletion of killer cell lectin-like receptor G1 (KLRG1)+ cells after the end of treatment with ABC008.

Efficacy, safety, HRQoL, and HRU assessments will be conducted. Blood samples will be obtained to evaluate the serum PK, PD, and immunogenicity of ABC008 throughout the study.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

272

Fase

Fase 2
Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

Australia
- New South Wales
  - Saint Leonards, New South Wales, Australia, 2065
    - Royal North Shore Hospital
- Queensland
  - Herston, Queensland, Australia, 4006
    - Royal Brisbane and Women's Hospital
- Western Australia
  - Nedlands, Western Australia, Australia, 6009
    - Perron Institute for Neurological and Translational Science
Belgio
- - Ghent, Belgio, 9000
    - AZ Sint-Lucas & Volkskliniek
Canada
- Alberta
  - Calgary, Alberta, Canada, 3M 1M4
    - Heritage Medical Research Clinic - University of Calgary
- Quebec
  - Montreal, Quebec, Canada, H4A 3T2
    - Genge Partners Inc.
Francia
- - Paris, Francia, 75013
    - Hospital Pitie-Salpetriere - AP-HP
Germania
- - Berlin, Germania, 15562
    - Krankenhaus und Poliklinik Rüdersdorf GmbH
  - Düsseldorf, Germania, 40225
    - University Hosptial Duesseldorf
Regno Unito
- - London, Regno Unito, WC1N 3BG
    - University College London Hospitals NHS Foundation Trust, National Hospital for Neurology and Neurosurgery (NHNN)
  - Salford, Regno Unito, M6 8HD
    - Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust
Stati Uniti
- Arizona
  - Phoenix, Arizona, Stati Uniti, 85028
    - Neuromuscular Research Center
- California
  - Irvine, California, Stati Uniti, 92868
    - University of California Irvine Medical Center (UCIMC) - Amyotrophic Lateral Sclerosis (ALS) and Neuromuscular Center
  - Los Angeles, California, Stati Uniti, 90095
    - UCLA Medical Center
  - Los Angeles, California, Stati Uniti, 90033
    - Keck Hosptial of USC
  - Palo Alto, California, Stati Uniti, 94304
    - Stanford Neuroscience Medical Center
  - San Francisco, California, Stati Uniti, 94143
    - University of California, San Francisco
- Colorado
  - Aurora, Colorado, Stati Uniti, 80045
    - University of Colorado Hospital Anschutz Outpatient Pavillion
- Connecticut
  - New Haven, Connecticut, Stati Uniti, 06519
    - Yale School of Medicine
- Florida
  - Jacksonville, Florida, Stati Uniti, 32224
    - Mayo Clinic
- Illinois
  - Chicago, Illinois, Stati Uniti, 60611
    - Northwestern Memorial Hospital, Department of Neurology (Clinic)
- Kansas
  - Kansas City, Kansas, Stati Uniti, 66160
    - University of Kansas Medical
- Maryland
  - Baltimore, Maryland, Stati Uniti, 21224
    - Johns Hopkins Bayview Medical Center
  - Baltimore, Maryland, Stati Uniti, 21287
    - Johns Hopkins University School of Medicine
- Massachusetts
  - Boston, Massachusetts, Stati Uniti, 02114
    - Neuromuscular Diagnostic Center - Massachusetts General Hospital
  - Boston, Massachusetts, Stati Uniti, 021158
    - Brigham and Womens Hospital
- Minnesota
  - Rochester, Minnesota, Stati Uniti, 55905
    - Mayo Clinic
- Missouri
  - St Louis, Missouri, Stati Uniti, 63110
    - Washington University School of Medicine
- Nebraska
  - Omaha, Nebraska, Stati Uniti, 98198
    - University of Nebraska Medical Center
- New York
  - New York, New York, Stati Uniti, 10021
    - Hospital for Special Surgery
  - New York, New York, Stati Uniti, 10032
    - Columbia University Medical Center / The Neurological Institute of New York
- North Carolina
  - Durham, North Carolina, Stati Uniti, 27710
    - Duke Neurological Disorders Clinic -1L
  - Winston-Salem, North Carolina, Stati Uniti, 27157
    - Wake Forrest School of Medicine
- Ohio
  - Cleveland, Ohio, Stati Uniti, 44106
    - University Hospitals Cleveland Medical Center
  - Columbus, Ohio, Stati Uniti, 43210
    - The Ohio State University Wexner Medical Center
- Oregon
  - Portland, Oregon, Stati Uniti, 97239
    - Oregon Health & Science University
- Pennsylvania
  - Hershey, Pennsylvania, Stati Uniti, 17033
    - Penn State Health Milton S. Hershey Medical Center
  - Philadelphia, Pennsylvania, Stati Uniti, 19104
    - University of Pennsylvania
  - Pittsburgh, Pennsylvania, Stati Uniti, 15213
    - UPMC Arthritis and Autoimmunity Center, Falk Clinic
- Texas
  - Austin, Texas, Stati Uniti, 78759
    - Austin Neuromuscular Center
  - Dallas, Texas, Stati Uniti, 75206
    - Texas Neurology
  - Houston, Texas, Stati Uniti, 77030
    - Nerve and Muscle Center of Texas
- Virginia
  - Henrico, Virginia, Stati Uniti, 23233
    - Virginia Commonwealth University
- Washington
  - Seattle, Washington, Stati Uniti, 98195
    - University of Washington Medical Center - Montlake
- Wisconsin
  - Milwaukee, Wisconsin, Stati Uniti, 53226
    - Medical College of Wisconsin

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

40 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

Adult males and females age >40 years at the time of the first dose of study medication;
Weight >40 and <150 kg;
Diagnosis of either clinico-pathologically defined IBM, clinically defined IBM, or probable IBM according to the European Neuromuscular Centre (ENMC) IBM 2011 research diagnostic criteria (Rose et al., 2013). Documented histopathology results must be available prior to Baseline (Day 1) to confirm eligibility;
Able to arise from a chair (with armrests), with use of their arms but without support from another person or device (e.g., cane, walking stick), at Screening and Baseline (Day 1);
Able to walk 3 meters, turn around, walk back to the chair, and sit down, with or without assistive device. Once arisen from the chair, subject may use any walking device but cannot be supported by another person, furniture, or a wall;

Exclusion Criteria:

Any other form of myositis or myopathy other than IBM, e.g., metabolic or drug-induced myopathy, drug-induced myositis, anti-synthetase syndrome, polymyositis or dermatomyositis, cancer-associated myositis (myositis diagnosed within 3 years, either before or after), myositis in overlap with another autoimmune disease (e.g., systemic lupus, systemic sclerosis, rheumatoid arthritis), or muscular dystrophy;
Any condition, e.g., severe degenerative arthritis with limited range of motion, which precludes the ability to quantitate muscle strength or perform functional assessments (e.g., mTUG), in the Investigator's opinion;.
Presence of another autoimmune or autoinflammatory disease other than indication under study, e.g., rheumatoid arthritis, psoriatic arthritis, axial spondyloarthropathy, inflammatory bowel disease, systemic lupus erythematosus. Subjects with Sjogren's syndrome, T-cell large granular lymphocyte leukemia (T-LGLL), or well-controlled thyroid disease are permitted;

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

Scopo principale: Trattamento
Assegnazione: Randomizzato
Modello interventistico: Assegnazione parallela
Mascheramento: Quadruplicare

Armi e interventi

Gruppo di partecipanti / Arm Gruppo di partecipanti / Arm Un gruppo o sottogruppo di partecipanti a uno studio clinico che riceve un intervento/trattamento specifico o nessun intervento, secondo il protocollo dello studio.	Intervento / Trattamento Intervento / Trattamento Un processo o un'azione che è al centro di uno studio clinico. Gli interventi includono farmaci, dispositivi medici, procedure, vaccini e altri prodotti sperimentali o già disponibili. Gli interventi possono anche includere approcci non invasivi, come l'educazione o la modifica della dieta e dell'esercizio fisico.
Comparatore attivo: 0.5 mg/kg ABC008 Part A - ABC008 N=12 Part B - ABC008 N= 67	Droga: ABC008 Given by subcutaneous injection
Comparatore attivo: 2.0 mg/kg ABC008 Part A - ABC008 N=12 Part B - ABC008 N= 67	Droga: ABC008 Given by subcutaneous injection
Comparatore placebo: Placebo Part A - Placebo N= 6 Part B - Placebo N= 67	Droga: ABC008 Given by subcutaneous injection

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato	Misura Descrizione	Lasso di tempo
Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Lasso di tempo: Up to Week 80	An adverse event (AE) was defined as any untoward medical occurrence in any participant participating in a clinical investigation, regardless of the suspected cause. An AE was therefore any unfavorable and unintended sign, symptom, disease, concurrent illness, or clinically significant abnormal laboratory finding that emerged or worsened during the study. A TEAE was defined as an AE that first occurred or worsened after initiation of study drug.	Up to Week 80
Part A: Number of Participants With TEAEs by Severity Lasso di tempo: Up to Week 80	A TEAE was defined as an AE that first occurred or worsened after initiation of study drug and was graded by severity per protocol-specified Common Terminology Criteria for Adverse Events (CTCAE) criteria: Grade 1, Mild (asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated); Grade 2, Moderate (minimal, local, or noninvasive intervention indicated; limited age-appropriate instrumental activities of daily living (ADL)); Grade 3, Severe or medically significant (medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care ADL); Grade 4, Life-threatening (threatening consequences; urgent intervention indicated); and Grade 5, Death (death related to an AE).	Up to Week 80
Part A: Number of Participants With TEAEs Related to Study Drug Lasso di tempo: Up to Week 80	An AE was defined as any untoward medical occurrence in any participant participating in a clinical investigation, regardless of the suspected cause. An AE was therefore can be any unfavorable and unintended sign, symptom, disease, concurrent illness, or clinically significant abnormal laboratory finding that emerged or worsened during the study. A TEAE was defined as an AE that first occurred or worsened after initiation of study drug. An AE with missing relationship to study drug was considered as related to study drug.	Up to Week 80
Part A: Mean Change From Baseline in the Inclusion Body Myositis Functional Rating Scale (IBMFRS) Total Score at Week 76 Lasso di tempo: Baseline (Day 1) and at Week 76	The IBMFRS was used as an ordinal rating scale to determine participant's assessments of their capabilities. It included 10 measures (swallowing, handwriting, cutting food and handling utensils, fine motor tasks, dressing, hygiene, turning in bed and adjusting covers, changing position from sitting to standing, walking, and climbing stairs) graded on a Likert scale (a psychometric tool) from 0 (being unable to perform) to 4 (normal). The sum of the 10 items provided a value between 0 and 40, with a higher score representing less functional limitation or better functional status. Baseline value was defined as the last non-missing valid value prior to first administration of study treatment (on Day 1). Change from Baseline was calculated as the data collected at post-randomization visits minus the Baseline.	Baseline (Day 1) and at Week 76
Part B: Number of Participants With TEAEs Lasso di tempo: Day 1 to Week 80	An AE was defined as any untoward medical occurrence in any participant participating in a clinical investigation, regardless of the suspected cause. An AE was therefore can be any unfavorable and unintended sign, symptom, disease, concurrent illness, or clinically significant abnormal laboratory finding that emerged or worsened during the study. A TEAE was defined as an AE that first occurred or worsened after initiation of study drug.	Day 1 to Week 80
Part B: Number of Participants With TEAEs by Severity Lasso di tempo: Day 1 to Week 80	A TEAE was defined as an AE that first occurred or worsened after initiation of study drug and was graded by severity per protocol-specified CTCAE criteria: Grade 1, Mild (asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated); Grade 2, Moderate (minimal, local, or noninvasive intervention indicated; limited age-appropriate instrumental ADL); Grade 3, Severe or medically significant (medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; or limiting self-care ADL); Grade 4, Life-threatening (threatening consequences; urgent intervention indicated); and Grade 5, Death (death related to an AE).	Day 1 to Week 80
Part B: Number of Participants With TEAEs Related to Study Drug Lasso di tempo: Day 1 to Week 80	An AE was defined as any untoward medical occurrence in any participant participating in a clinical investigation, regardless of the suspected cause. An AE was therefore can be any unfavorable and unintended sign, symptom, disease, concurrent illness, or clinically significant abnormal laboratory finding that emerged or worsened during the study. A TEAE was defined as an AE that first occurred or worsened after initiation of study drug. An AE with missing relationship to study drug was considered as related to study drug.	Day 1 to Week 80
Part B: Mean Change From Baseline in the IBMFRS Total Score at Week 76 Lasso di tempo: Baseline (Day 1) and Up to Week 76	The IBMFRS was used as an ordinal rating scale to determine participant's assessments of their capabilities. It included 10 measures (swallowing, handwriting, cutting food and handling utensils, fine motor tasks, dressing, hygiene, turning in bed and adjusting covers, changing position from sitting to standing, walking, and climbing stairs) graded on a Likert scale (a psychometric tool) from 0 (being unable to perform) to 4 (normal). The sum of the 10 items provided a value between 0 and 40, with a higher score representing less functional limitation or better functional status. Baseline value was defined as the last non-missing valid value prior to first administration of study treatment (on Day 1). Change from Baseline was calculated as the data collected at post-randomization visits minus the Baseline.	Baseline (Day 1) and Up to Week 76
Part C: Time to PD Recovery Lasso di tempo: Up to Week 24	Recovery was defined as the return of KLRG1+ cell counts toward baseline levels during the PD follow-up period.	Up to Week 24

Misure di risultato secondarie

Misura del risultato	Misura Descrizione	Lasso di tempo
Part A and B: Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs) Lasso di tempo: Up to Week 80	A TESAE was defined as a serious AE that first occurred or worsened after initiation of study drug and met seriousness criteria per protocol (including death, life-threatening event, hospitalization or prolongation of hospitalization, persistent or significant disability/incapacity, congenital anomaly, or other medically important event).	Up to Week 80
Part A and B: Number of Participants With TEAEs With Onset Within 24 Hours From the Start of Any Study Medication Administration Lasso di tempo: Within 24 hours following each dose, Up to Week 80	A TEAE was defined as an AE that first occurred or worsened after initiation of study drug, with onset assessed within 24 hours following the dosing.	Within 24 hours following each dose, Up to Week 80
Part A and B: Number of Participants With TEAEs Leading to Study Discontinuation Lasso di tempo: Up to Week 80	A TEAE was defined as an AE that first occurred or worsened after initiation of study drug that led to discontinuation of study.	Up to Week 80
Part A and B: Change From Baseline in Hematology Parameters - Absolute Neutrophil Count, Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils, and Platelets Lasso di tempo: Baseline (Day 1) to Week 76	Blood samples were collected for the analysis of hematology parameters: Absolute Neutrophil Count, Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils, and Platelets. Baseline value was defined as the last non-missing valid value prior to first administration of study treatment (on Day 1). Change from Baseline was calculated as the data collected at post-randomization visits minus the Baseline.	Baseline (Day 1) to Week 76
Part A and B: Change From Baseline in Hematology Parameter - Erythrocytes Lasso di tempo: Baseline (Day 1) to Week 76	Blood samples were collected for the analysis of hematology parameter Erythrocytes. Baseline value was defined as the last non-missing valid value prior to first administration of study treatment (on Day 1). Change from Baseline was calculated as the data collected at post-randomization visits minus the Baseline.	Baseline (Day 1) to Week 76
Part A and B: Change From Baseline in Hematology Parameters - Hemoglobin and Erythrocyte Mean Corpuscular Hemoglobin Concentration Lasso di tempo: Baseline (Day 1) to Week 76	Blood samples were collected for the analysis of hematology parameters: Hemoglobin and Erythrocyte Mean Corpuscular Hemoglobin Concentration. Baseline value was defined as the last non-missing valid value prior to first administration of study treatment (on Day 1). Change from Baseline was calculated as the data collected at post-randomization visits minus the Baseline.	Baseline (Day 1) to Week 76
Part A and B: Change From Baseline in Hematology Parameter - Erythrocyte Mean Corpuscular Hemoglobin Lasso di tempo: Baseline (Day 1) to Week 76	Blood samples were collected for the analysis of hematology parameters: Hemoglobin and Erythrocyte Mean Corpuscular Hemoglobin. Baseline value was defined as the last non-missing valid value prior to first administration of study treatment (on Day 1). Change from Baseline was calculated as the data collected at post-randomization visits minus the Baseline.	Baseline (Day 1) to Week 76
Part A and B: Change From Baseline in Hematology Parameters - Erythrocyte Mean Corpuscular Volume Lasso di tempo: Baseline (Day 1) to Week 76	Blood samples were collected for the analysis of hematology parameter Erythrocyte Mean Corpuscular Volume. Baseline value was defined as the last non-missing valid value prior to first administration of study treatment (on Day 1). Change from Baseline was calculated as the data collected at post-randomization visits minus the Baseline.	Baseline (Day 1) to Week 76
Part A and B: Change From Baseline in Hematology Parameters - Hematocrit Lasso di tempo: Baseline (Day 1) to Week 76	Blood samples were collected for the analysis of hematology parameter Hematocrit. Baseline value was defined as the last non-missing valid value prior to first administration of study treatment (on Day 1). Change from Baseline was calculated as the data collected at post-randomization visits minus the Baseline.	Baseline (Day 1) to Week 76
Part A and B: Change From Baseline in Blood Chemistry Parameters - Alanine Aminotransferase (ALT), Aldolase, Gamma Glutamyl Transferase (GGT), Lactate Dehydrogenase, Aspartate Aminotransferase (AST) Lasso di tempo: Baseline (Day 1) to Week 76	Blood samples were collected for the analysis of blood chemistry parameters: ALT, Aldolase, AST, GGT and Lactate Dehydrogenase. Baseline value was defined as the last non-missing valid value prior to first administration of study treatment (on Day 1). Change from Baseline was calculated as the data collected at post-randomization visits minus the Baseline.	Baseline (Day 1) to Week 76
Part A and B: Change From Baseline in Blood Chemistry Parameters - Albumin and Protein Lasso di tempo: Baseline (Day 1) to Week 76	Blood samples were collected for the analysis of blood chemistry parameters Albumin and Protein. Baseline value was defined as the last non-missing valid value prior to first administration of study treatment (on Day 1). Change from Baseline was calculated as the data collected at post-randomization visits minus the Baseline.	Baseline (Day 1) to Week 76
Part A and B: Change From Baseline in Blood Chemistry Parameters - Alkaline Phosphatase and Creatine Kinase (CK) Lasso di tempo: Baseline (Day 1) to Week 76	Blood samples were collected for the analysis of blood chemistry parameters Alkaline Phosphatase and CK. Baseline value was defined as the last non-missing valid value prior to first administration of study treatment (on Day 1). Change from Baseline was calculated as the data collected at post-randomization visits minus the Baseline.	Baseline (Day 1) to Week 76
Part A and B: Change From Baseline in Blood Chemistry Parameters - Bicarbonate, Calcium, Chloride, Glucose, Potassium, Sodium and Urea Lasso di tempo: Baseline (Day 1) to Week 76	Blood samples were collected for the analysis of blood chemistry parameters: Bicarbonate, Calcium, Chloride, Glucose, Potassium, and Urea. Baseline value was defined as the last non-missing valid value prior to first administration of study treatment (on Day 1). Change from Baseline was calculated as the data collected at post-randomization visits minus the Baseline.	Baseline (Day 1) to Week 76
Part A and B: Change From Baseline in Blood Chemistry Parameters - Bilirubin, Creatinine and Urate Lasso di tempo: Baseline (Day 1) to Week 76	Blood samples were collected for the analysis of blood chemistry parameters: Bilirubin, Creatinine, and Urate. Baseline value was defined as the last non-missing valid value prior to first administration of study treatment (on Day 1). Change from Baseline was calculated as the data collected at post-randomization visits minus the Baseline.	Baseline (Day 1) to Week 76
Part A and B: Change From Baseline in Urinalysis Parameter - pH Lasso di tempo: Baseline (Day 1) to Week 76	Urine samples were collected for the analysis of Urinalysis parameter: pH. Baseline value was defined as the last non-missing valid value prior to first administration of study treatment (on Day 1). Change from Baseline was calculated as the data collected at post-randomization visits minus the Baseline.	Baseline (Day 1) to Week 76
Part A and B: Change From Baseline in Urinalysis Parameter- Specific Gravity Lasso di tempo: Baseline (Day 1) to Week 76	Urine samples were collected for the analysis of Urinalysis parameters- specific gravity. Baseline value was defined as the last non-missing valid value prior to first administration of study treatment (on Day 1). Change from Baseline was calculated as the data collected at post-randomization visits minus the Baseline.	Baseline (Day 1) to Week 76
Part A and B: Change From Baseline in Complement Parameters - C3 and C4 Lasso di tempo: Baseline (Day 1) to Week 76	Blood samples were collected for the analysis of complement parameters included C3 and C4. Baseline value was defined as the last non-missing valid value prior to first administration of study treatment (on Day 1). Change from Baseline was calculated as the data collected at post-randomization visits minus the Baseline.	Baseline (Day 1) to Week 76
Part A and B: Change From Baseline in Complement Parameters - Hemolytic Complement Filtration (CH50) Lasso di tempo: Baseline (Day 1) to Week 76	Blood samples were collected for the analysis of complement parameter- hemolytic complement filtration (CH50). Baseline value was defined as the last non-missing valid value prior to first administration of study treatment (on Day 1). Change from Baseline was calculated as the data collected at post-randomization visits minus the Baseline.	Baseline (Day 1) to Week 76
Part A and B: Change From Baseline in C Reactive Protein (CRP) Lasso di tempo: Baseline (Day 1) to Week 76	Blood samples were collected for the analysis of blood chemistry parameter- CRP. Baseline value was defined as the last non-missing valid value prior to first administration of study treatment (on Day 1). Change from Baseline was calculated as the data collected at post-randomization visits minus the Baseline.	Baseline (Day 1) to Week 76
Part A and B: Number of Participants With Clinically Significant Changes in Vital Signs Lasso di tempo: Up to Week 76	Vital signs were planned to be measured after 5 minutes of rest and taken in the same position throughout the study. Vital signs included blood pressure, pulse, temperature, and respiration rate. Clinically significant changes in vital signs were defined according to protocol-specified criteria for abnormal values (or clinically significant worsening from baseline) as determined by the Investigator.	Up to Week 76
Part A and B: Change From Baseline in Electrocardiogram (ECG) Mean Heart Rate Lasso di tempo: Baseline (Day 1) to Week 76	Triplicate 12-lead ECG was recorded with the participant in a supine position for at least 5 minutes. Changes in ECG parameters were defined according to protocol-specified criteria for change from baseline values as determined by the Investigator. Baseline value was defined as the last non-missing valid value prior to first administration of study treatment (on Day 1). Change from Baseline was calculated as the data collected at post-baseline visits minus the Baseline.	Baseline (Day 1) to Week 76
Part A and B: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and Interval Corrected Using Fridericia's Formula (QTcF) Interval Lasso di tempo: Baseline (Day 1) to Week 76	Triplicate 12-lead ECG was recorded with the participant in a supine position for at least 5 minutes. Changes in ECG parameters were defined according to protocol-specified criteria for change from baseline values as determined by the Investigator. Baseline value was defined as the last non-missing valid value prior to first administration of study treatment (on Day 1). Change from Baseline was calculated as the data collected at post-randomization visits minus the Baseline.	Baseline (Day 1) to Week 76
Part A and B: Number of Participants With Treatment-emergent Adverse Events of Special Interest (AESI) Lasso di tempo: Up to Week 80	An AE was defined as any untoward medical occurrence in any participant partaking in a clinical investigation, regardless of the suspected cause. An AE was therefore can be any unfavorable and unintended sign, symptom, disease, concurrent illness, or clinically significant abnormal laboratory finding that emerged or worsened during the study. AESIs included injection site reactions, systemic injection reactions (e.g., hypersensitivity, systemic inflammatory response), and infection.	Up to Week 80
Part A and B: Mean Change From Baseline in the Manual Muscle Testing - 12 (MMT-12) Score at Week 76 Lasso di tempo: Baseline (Day 1) and up to Week 76	Manual Muscle Testing - 12 assessed the muscle strength across the muscle groups that included neck flexion and both right and left shoulder abduction, elbow flexion, elbow extension, wrist extension, wrist flexion, flexor pollicis longus, hip flexors, hip abduction, hip extension, knee extension, and ankle dorsiflexion. Scores were calculated by summing the outcomes, with the Investigator providing the score, on a scale of 0 (no contraction) to 5 (normal strength), which is then converted by a standard procedure to a Kendall score equivalent on a scale of 0 to 10. Individual scores are summed to generate a total score ranging from 0 to 60. A higher score reflects better muscle strength. Baseline value was defined as the last non-missing valid value prior to first administration of study treatment (on Day 1). Change from Baseline was calculated as the data collected at post-randomization visits minus the Baseline.	Baseline (Day 1) and up to Week 76
Part A and B: Mean Change From Baseline in the Hand Grip Strength Score by Dynamometry at Week 76 Lasso di tempo: Baseline (Day 1) and up to Week 76	Grip strength was assessed using a handheld dynamometer which provided a precise measurement of the force that a muscle can exert and reflects muscle strength of the hand. Positive values indicated increased grip strength and negative values indicated decreased grip strength. Baseline value was defined as the last non-missing valid value prior to first administration of study treatment (on Day 1). Change from Baseline was calculated as the data collected at post-randomization visits minus the Baseline.	Baseline (Day 1) and up to Week 76
Part A and B: Mean Change From Baseline in the Quadriceps Strength Score by Dynamometry at Week 76 Lasso di tempo: Baseline (Day 1) and up to Week 76	Quadriceps strength was measured using a dynamometer which provided the applied force of leg extension and reflects muscle strength of the dominant leg. Positive values indicated increased strength and negative values indicated decreased strength. Baseline value was defined as the last non-missing valid value prior to first administration of study treatment (on Day 1). Change from Baseline was calculated as the data collected at post-randomization visits minus the Baseline.	Baseline (Day 1) and up to Week 76
Part A and B: Mean Change From Baseline in Modified Timed Up and Go Test (mTUG) at Week 76 Lasso di tempo: Baseline (Day 1) and up to Week 76	The mTUG assessed functional mobility by measuring the time required for a participant to rise from a standard armchair, walk 3 meters, turn around, walk back to the chair, and sit down (assistive devices permitted after standing, but no support from a caregiver, or a wall). Negative values indicated faster performance and positive values indicated slower performance. Baseline value was defined as the last non-missing valid value prior to first administration of study treatment (on Day 1). Change from Baseline was calculated as the data collected at post-randomization visits minus the Baseline.	Baseline (Day 1) and up to Week 76

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Abcuro, Inc.

Collaboratori

Syneos Health

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Collegamenti utili

<p>Study Website</p>

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

28 febbraio 2023

Completamento primario (Effettivo)

6 novembre 2025

Completamento dello studio (Effettivo)

27 novembre 2025

Date di iscrizione allo studio

Primo inviato

1 febbraio 2023

Primo inviato che soddisfa i criteri di controllo qualità

1 febbraio 2023

Primo Inserito (Effettivo)

10 febbraio 2023

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

1 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

8 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

ABC008-IBM-201

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Uno studio per valutare l'efficacia e la sicurezza di ABC008 per la miosite da corpi inclusi

Uno studio di fase II/III randomizzato, in doppio cieco, controllato con placebo, multicentrico per valutare l'efficacia e la sicurezza di ABC008 nel trattamento di soggetti con miosite da corpi inclusi

Panoramica dello studio

Stato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Tipo di studio

Iscrizione (Effettivo)

Fase

Contatti e Sedi

Luoghi di studio

Criteri di partecipazione

Criteri di ammissibilità

Età idonea allo studio

Accetta volontari sani

Sessi ammissibili allo studio

Descrizione

Piano di studio

Come è strutturato lo studio?

Dettagli di progettazione

Numero di armi

Armi e interventi

Gruppo di partecipanti / Arm

Intervento / Trattamento

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato

Misura Descrizione

Lasso di tempo

Misure di risultato secondarie

Misura del risultato

Misura Descrizione

Lasso di tempo

Collaboratori e investigatori

Sponsor

Collaboratori

Pubblicazioni e link utili

Collegamenti utili

Studiare le date dei record

Studia le date principali

Inizio studio (Effettivo)

Completamento primario (Effettivo)

Completamento dello studio (Effettivo)

Date di iscrizione allo studio

Primo inviato

Primo inviato che soddisfa i criteri di controllo qualità

Primo Inserito (Effettivo)

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

Ultimo aggiornamento inviato che soddisfa i criteri QC

Ultimo verificato

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti